FDA Approves Sickle Cell Gene Therapy for Young Kids

(MedPage Today) -- The FDA on Wednesday expanded the approval for exagamglogene autotemcel (exa-cel, Casgevy) in severe sickle cell disease with recurrent vaso-occlusive crises and transfusion-dependent beta thalassemia to include children 2 years...